Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q1 FY2018 Earnings Presentation
15 slides from Advanced Enzyme Technologies's earnings presentation, Sep 11, 2017
Slide 1: Earnings Presentation Q1FY18
Earnings Presentation Q1FY18
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: Company Overview: What are enzymes?
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve efficie
Slide 4: A Rising Global Star Amongst Top 15 Global Enzyme Companies
Advanced Enzyme Technologies Limited – A Rising Global Star Revenue (₹ mn) 1st Indian enzyme company Highest market share in India Listed integrated enzyme player globally 2nd 2nd 3,314 2,204 Amongst Top 15 Global Enzyme Companies Manufacturing Units – 7 R&D Units – 7 FY 2013 FY 2017 India - 5 USA -
Slide 5: Board of Directors
Board of Directors Mr. Vasant Rathi Mr. C L Rathi Mrs. Savita Rathi Mr. Mukund M. Kabra Chairman and Non- Executive Director Managing Director Whole-time Director Whole-time Director Mr. Vasant Laxminarayan Rathi is the Mr. Chandrakant Laxminarayan Rathi, is Mrs. Savita Chandrakant Rathi, is the Mr.
Slide 6: Management Team
Management Team A double graduate, Piyush first completed his Bachelors in Maths from Mumbai University and then in Finance from Michigan Tech University, USA. Subsequently he completed his MBA from SCMHRD and joined Advanced Enzymes in April 2005. In 2007 and in 2010, Piyush took charge of the Huma
Slide 7: Results Summary – Q1FY18
Results Summary – Q1FY18 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 511 278 941 755 299 163 Q1FY17 Q1FY18 Q1FY17 Q1FY18 Q1FY17 Q1FY18 *Revenue excluding excise duty Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Food Industrial Processing -24% (19%) (23%) 52% (35%) Q1FY18 109 551 46 49 Q1
Slide 8: Revenue Split
Revenue Split Q1FY18 Q1FY17 Segmental Revenue Split (%) Segmental Revenue Split (%) 7% 14% 8% 14% 6% 3% 73% 75% Animal HC Human HC Food Industrial Processing Animal HC Human HC Food Industrial Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 2% 4% 3% 27% 42% 65% 3% 51% 2%
Slide 9: Profit & Loss (Consolidated) – Q1FY18
Profit & Loss (Consolidated) – Q1FY18 ₹ in Million except per share data Q1FY18 Q1FY17 Particulars Y-o-Y (%) Unaudited Unaudited Income from Operations 802 968 (17) Expenses 544 492 11 Profit from Operations before Other Income, Finance Costs and 258 476 (46) Exceptional Item Other Income 3 4 (25) P
Slide 10: Top Customer – Trend Analysis
Top Customer – Trend Analysis ₹ in Million Year Q1 Q2 Q3 Q4 Total FY18 66 Expected to grow by 10-15% annually (in $ terms) FY17 375 278 2 135 790 FY16 137 127 211 237 712 FY15 58 31 73 60 222 Average Exchange rate: 2015 - $1 = ₹ 61.15 2016 - 1$ = ₹ 65.46 2017 - $1 = ₹ 67.09 2018 - $1 = ₹ 64.46 (upto
Slide 11: Financial Performance – FY17
Financial Performance – FY17 ₹ in Million Revenue from Operations 2500 EBIDTA & EBIDTA Margin (%) 48% 47% 46% 47% 3,314 2000 46% 2,938 43% 45% 2,204 2,394 2,231 1500 43% 1530 44% 1000 42% 1,389 43% 943 1,031 42% 500 931 41% 40% 0 39% FY 13 FY 14 FY 15 FY 16 FY 17 FY 13 FY 14 FY 15 FY 16 FY 17 EBIDTA
Slide 12: Strong Financial Performance – FY17
Strong Financial Performance – FY17 Net Working Capital (Days) Net Worth (₹ mn) 128 4,602 119 2,781 112 110 109 2,120 1,634 1,674 FY 13 FY 14 FY 15 FY 16 FY 17 FY 13 FY 14 FY 15 FY 16 FY 17 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 31% 28% 27% 1.1 26% 1.0 25% 28% 24% 0.5 20% 0.4 13% 0.1 FY 13 FY
Slide 13: Evoxx Technologies GmbH – Acquisition
Evoxx Technologies GmbH – Acquisition • Advanced Enzymes Technologies Ltd. acquired 100% stake in Evoxx Technologies GmbH for a consideration of € 7.65 million • The purchase is effected through its wholly owned subsidiary Advanced Enzymes Europe B.V. • Evoxx is an industrial biotech company focussi
Slide 14: Shareholder Information
Shareholder Information Stock Data (As on 30th June 2017) Top Institutional Holders Market Capitalization (₹) 36,185 mn Institutions OS (%) Dsp Blackrock Micro Cap Fund 2.10 Shares Outstanding 111.63 mn Reliance Capital Trustee Co. Ltd-a/C 1.21 Reliancesmall Cap Fund Free Float 23.15% The Nomura Tru
Slide 15: Thank You
Thank You Advanced Enzymes 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159
Advanced Enzyme Technologies — Q1 FY2018 Earnings Presentation on 6ix